Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07220902 · ClinicalTrials.gov registry record · Phase 3
Levetiracetam Compared to Magnesium Sulfate for Prevention of Eclamptic Seizure
A Phase 3 study, sponsored by Nebraska Methodist Health System.
- Not yet
- Registry status
- Phase 3
- Development phase
- 1,240
- Enrollment target
NCT07220902: Clinical Trial Phase 3 study, sponsored by Nebraska Methodist Health System.
NCT07220902 is a Phase 3 study that has not yet begun recruiting, run by Nebraska Methodist Health System. The registered enrollment target is 1,240 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (61% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07220902, a Phase 3 study, has not yet begun recruiting, sponsored by Nebraska Methodist Health System.
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,240 participants
- Enrollment target
Study Summary
The goal of this study is to compare levetiracetam to magnesium sulfate for the prevention of eclamptic seizures in pregnant persons with severe preeclampsia that are 32 or more weeks pregnant. This is an equivalence study so our primary goal is to see no difference in the incidence of seizure in the two groups. Since side effects can be a significant problem with magnesium sulfate and these patients are at significant risk of life threatening complications, we also plan to evaluate several secondary outcomes in the mothers and the babies, including: severe allergic reaction, magnesium toxicity, ICU admission, hospital readmission, transfusion for any reason, pulmonary edema, cardiomyopathy, Posterior Reversible Encephalopathy Syndrome, eclamptic seizure, loss of vision, stroke, renal injury requiring dialysis, cardiac arrest, maternal death, unexpected stillbirth or neonatal death, NICU admission, Apgars and length of neonatal respiratory support.
Primary Outcome
Seizure based on clinical diagnosis by managing physician. It will be considered and eclamptic seizure for purposes of the study if it occurs following enrollment in the study.
Interventions
- DRUG Levetiracetam
- DRUG magnesium sulfate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,240 participants |
| Start Date | 2026-01-01 |
| Est. Completion | 2034-07 |
| Phase | Phase 3 |
What is known before NCT07220902 opens enrollment
NCT07220902 is an interventional study that assigns participants to a tested intervention. Its 1,240 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (61% higher).
The record links to 0 conditions, and to 2 interventions - of which Levetiracetam is the first listed.
NCT07220902 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07220902 about?
NCT07220902 is a clinical study titled "Levetiracetam Compared to Magnesium Sulfate for Prevention of Eclamptic Seizure". The goal of this study is to compare levetiracetam to magnesium sulfate for the prevention of eclamptic seizures in pregnant persons with severe preeclampsia that are 32 or more weeks pregnant. This is an equivalence study so our primary goal is to see no difference in the incidence of seizure in th...
What is the current status of trial NCT07220902?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 1,240 participants. The study started on 2026-01-01. Estimated completion is 2034-07.
What interventions are being tested in trial NCT07220902?
The interventions under investigation include: Levetiracetam (DRUG), magnesium sulfate (DRUG).
Who is sponsoring clinical trial NCT07220902?
This trial is sponsored by Nebraska Methodist Health System, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07220902's enrollment target sits among peer trials
1,240 213th of 2000 higher than 1,787 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06368245 · 1,244 participants
Durability of Suppl. Rod Constructs-SuppleMentAry Rod Technique for Long-segment Posterior Instrumented Spinal Fusions
- NCT05456841 · 1,232 participants · NA
Empathic Communication Skills (ECS) Training
- NCT02743858 · 1,250 participants
Lymphedema Surveillance Study
- NCT04670874 · 1,250 participants
Quality of Life in Cutaneous Lymphoma Patients Using the Skindex29
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI